211 related articles for article (PubMed ID: 26829942)
21. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
22. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
[TBL] [Abstract][Full Text] [Related]
23. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
Tosh JC; Longworth LJ; George E
Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
[TBL] [Abstract][Full Text] [Related]
24. Special funding schemes for innovative medical devices in French hospitals: the pros and cons of two different approaches.
Martelli N; van den Brink H
Health Policy; 2014 Jul; 117(1):1-5. PubMed ID: 24794738
[TBL] [Abstract][Full Text] [Related]
25. Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions.
Carletto A; Zanuzzi M; Sammarco A; Russo P
Int J Technol Assess Health Care; 2020 Dec; 36(6):560-568. PubMed ID: 32907656
[TBL] [Abstract][Full Text] [Related]
26. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
[TBL] [Abstract][Full Text] [Related]
27. A critical assessment framework to identify, quantify and interpret the sources of uncertainty in cost-effectiveness analyses.
Merész G; Dóczy V; Hölgyesi Á; Németh G
BMC Health Serv Res; 2022 Jun; 22(1):822. PubMed ID: 35752772
[TBL] [Abstract][Full Text] [Related]
28. Improving the Methods for the Economic Evaluation of Medical Devices.
Tarricone R; Callea G; Ogorevc M; Prevolnik Rupel V
Health Econ; 2017 Feb; 26 Suppl 1():70-92. PubMed ID: 28139085
[TBL] [Abstract][Full Text] [Related]
29. The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).
Ghabri S; Autin E; Poullié AI; Josselin JM
Pharmacoeconomics; 2018 Apr; 36(4):407-417. PubMed ID: 29247437
[TBL] [Abstract][Full Text] [Related]
30. The economic evaluation of medical devices: challenges.
Kingkaew P; Teerawattananon Y
J Med Assoc Thai; 2014 May; 97 Suppl 5():S102-7. PubMed ID: 24964706
[TBL] [Abstract][Full Text] [Related]
31. Exploring structural uncertainty in model-based economic evaluations.
Afzali HH; Karnon J
Pharmacoeconomics; 2015 May; 33(5):435-43. PubMed ID: 25601288
[TBL] [Abstract][Full Text] [Related]
32. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study.
Miners AH; Garau M; Fidan D; Fischer AJ
BMJ; 2005 Jan; 330(7482):65. PubMed ID: 15601681
[TBL] [Abstract][Full Text] [Related]
33. Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience.
Prinja S; Jyani G; Gupta N; Rajsekar K
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):859-868. PubMed ID: 33882762
[TBL] [Abstract][Full Text] [Related]
34. Health technology assessment in the United Kingdom.
Akehurst R
Value Health; 2010 Jun; 13 Suppl 1():S4-5. PubMed ID: 20618794
[No Abstract] [Full Text] [Related]
35. Handling uncertainty of the economic evaluation result: sensitivity analysis.
Limwattananon S
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S59-65. PubMed ID: 19253488
[TBL] [Abstract][Full Text] [Related]
36. Organisational impact: Definition and assessment methods for medical devices.
Roussel C; Carbonneil C; Audry A;
Therapie; 2016 Feb; 71(1):69-96. PubMed ID: 27080633
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity analysis for handling uncertainty in an economic evaluation.
Limwattananon S
J Med Assoc Thai; 2014 May; 97 Suppl 5():S59-64. PubMed ID: 24964700
[TBL] [Abstract][Full Text] [Related]
38. Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.
Bae S; Bae EY; Lim SH
Patient; 2014; 7(2):141-50. PubMed ID: 24578251
[TBL] [Abstract][Full Text] [Related]
39. Intrinsic properties of medical devices: considerations for economic evaluation.
Basu R; Eggington S
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):619-626. PubMed ID: 31721598
[No Abstract] [Full Text] [Related]
40. Incremental Cost-Effectiveness Ratio and Net Monetary Benefit: Promoting the Application of Value-Based Pricing to Medical Devices-A European Perspective.
Messori A; Trippoli S
Ther Innov Regul Sci; 2018 Nov; 52(6):755-756. PubMed ID: 29714590
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
